Skip to NavigationSkip to content

Roche's satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder

Published on 02/12/19 at 10:27am

Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a condition characterised by relapses which can lead to cumulative and permanent neurological damage and disability in affected patients.

Satralizumab can be self-administered once every four weeks via subcutaneous injection. In Phase 3 trials, 89% of patients receiving the therapy in combination with baseline immunosuppressant therapy were found to be relapse-free after 48 weeks of treatment; this finding extended to 78% and 74% of patients at week 96 and week 144, compared to 66%, 59% and 49% with placebo with baseline therapy.

Just eight of the 41 total participants receiving satralizumab plus baseline therapy reported a protocol-defined relapse (PDR), compared to 18 of the 42 placebo patients.

The study was also noted to be representative of the real-world adolescent and adult NMOSD community by including both aquaporin-4 seropositive and seronegative patients in its intent-to-treat population.

“The positive results from the pivotal SAkuraSky study of satralizumab support the hypothesis that IL-6 plays a key role in NMOSD, which is a debilitating and potentially fatal condition,” commented Dr Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “Satralizumab has shown robust efficacy sustained for 144 weeks across a broad patient population in two Phase 3 studies, whether given as a monotherapy or in combination with baseline therapy. We’re encouraged that satralizumab may soon provide a new treatment option for people living with NMOSD.”  

Satralizumab is currently under review in Europe and the US with decisions expected next year.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches